Should you hold CV Sciences (cvsi) stock?
The consensus among Wall Street equities research analysts is that investors should "hold" CV Sciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CVSI, but not buy additional shares or sell existing shares. View analyst ratings for CV Sciences or view top-rated stocks.
Is CV Sciences efficiently growing its dividend?
CV Sciences does not have a long track record of dividend growth. In the past three months, CV Sciences insiders have not sold or bought any company stock. Only 6.80% of the stock of CV Sciences is held by insiders. Only 0.02% of the stock of CV Sciences is held by institutions.
What does cvsi stand for?
CV Sciences, Inc. (CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced the appointment of Dr. Paul Blake to its Board of Directors effective October 21, 2019. “We are very pleased to have Dr.
When will cvsi go broke?
Well, The way I see this stock is, if we don’t get anything positive from congress or the FDA in the next 2 quarters, CVSI will be broke by the middle of 2022, or if by some miracle CVSI pulls a rabbit out of there hat, meaning $7.000.000,00 in sales in the 4th quarter to stop the bleeding, we can survive a few more quarters, Stuart is our Rabbit.
How High will CVSI stock go?
Their CVSI stock forecasts range from $0.17 to $0.17. On average, they expect CV Sciences' share price to reach $0.17 in the next twelve months. This suggests a possible upside of 431.3% from the stock's current price. View analysts' price targets for CV Sciences or view top-rated stocks among Wall Street analysts.
What does CV Sciences do?
We provide research based solutions for the well being of the planet. This is health transformed.
Is CV Sciences CBD good?
CV Sciences made it stand out by making sure the company delivers high-quality products to the masses always. As of September 2018, CV Sciences obtained the GRAS (Generally Recognized as Safe by FDA standards) designation on its CBD products.
Why is CV Sciences stock dropping?
The reported decline in sales for 2021, which dropped from $24.4 million in 2020 to $20.0 million last year, were chalked up to increased market competition, which is largely due to the uncertain regulatory environment for CBD, said the company.
Should I buy or sell CV Sciences stock right now?
2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CV Sciences in the last year. There are currently 2 hold ratings...
What is CV Sciences' stock price forecast for 2022?
2 brokerages have issued 1-year price targets for CV Sciences' stock. Their CVSI stock forecasts range from $0.17 to $0.17. On average, they antici...
How has CV Sciences' stock performed in 2022?
CV Sciences' stock was trading at $0.12 at the start of the year. Since then, CVSI shares have decreased by 62.5% and is now trading at $0.0450. V...
How were CV Sciences' earnings last quarter?
CV Sciences, Inc. (OTCMKTS:CVSI) issued its quarterly earnings results on Monday, May, 16th. The company reported ($0.02) EPS for the quarter, meet...
Who are CV Sciences' key executives?
CV Sciences' management team includes the following people: Mr. Joseph D. Dowling , CEO, Sec. & Director (Age 65, Pay $418.52k) Mr. Joerg Grasse...
Who are some of CV Sciences' key competitors?
Some companies that are related to CV Sciences include RegeneRx Biopharmaceuticals (RGRX) , Lotus Pharmaceuticals (LTUS) , Emerald Bioscience (E...
What other stocks do shareholders of CV Sciences own?
Based on aggregate information from My MarketBeat watchlists, some companies that other CV Sciences investors own include (CGC) , Aurora Cannabi...
What is CV Sciences' stock symbol?
CV Sciences trades on the OTCMKTS under the ticker symbol "CVSI."
How do I buy shares of CV Sciences?
Shares of CVSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBul...
About CV Sciences
Headlines
CV Sciences, Inc. engages in the development, manufacture, and sale of consumer and pharmaceutical products. It operates through the Consumer Products and Specialty Pharmaceutical segments. The Consumer Products segment includes manufacturing, marketing, and selling of hemp-based cannabidiol products through the PlusCBD brand.
CV Sciences (OTCMKTS:CVSI) Frequently Asked Questions
Is Medical Marijuana Really A Slippery Slope? CVSI Distribution Agreement with GNC
What is CV Sciences?
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CV Sciences in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CV Sciences stock.
Where is CV Sciences located?
CV Sciences, Inc. operates as a life science company in the United States. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The Consumer Products segment develops, manufactures, and markets plant-based dietary supplements and hemp-based cannabidiol (CBD) products under the PlusCBD name in various market sectors, including nutraceutical, beauty care, and specialty foods. It serves internet sales, direct-to-consumer health and wellness stores, collectives, cooperatives, master distributors, specialty retailers, and convenience stores, as well as food, drug, and mass merchandise retailers. The Specialty Pharmaceutical segment focuses on developing and commercializing cannabinoids to treat medical indications. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.
Is Medical Marijuana Really A Slippery Slope? CVSI Distribution Agreement with GNC
and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California. More... Sector.
The Week In Cannabis: Stocks Down, Republican Legalization Bill, Germany, Uruguay, Earnings, New ETF And More
The Best Daily Overview Of The Cannabis Space CV Sciences Announces New Distribution Agreement with GNC. $CVSI Massachusetts cannabis prices continue to fall Kentucky GOP Sen. Damon Thayer: "Medical cannabis is a slippery slope for recreational marijuana.”
Dry January Got You Down? Cannabis To The Rescue With Tokes, Yummy Gummies And More
Below is a recap of the main news related to the cannabis industry and markets for the week of November 15, 2021. Contents
CV Sciences, Inc. Appoints Haskell & White LLP as Auditor
After the hustle and bustle of the holidays, many people are looking to curtail their consumption of alcohol and are therefore partaking in Dry January. Who Thought Of Laying Off Booze For A Month?
Here's Why CV Sciences, Inc. (CVSI) Looks Ripe for Bottom Fishing
SAN DIEGO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products...
CV Sciences 3Q Financials Continue To Improve Cost Structure, Praises California CBD Legislation
CV Sciences, Inc. (CVSI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement amon...
CV Sciences, Inc. (CVSI) Reports Break-Even Earnings for Q3
CV Sciences, Inc. (OTCQB:CVSI), a supplier and manufacturer of hemp cannabidiol (CBD) products, announced its financial results for the quarter on Monday, Nov 15. Third Quarter 2021 and Recent Financial...
CV Sciences, Inc. Announces Convertible Note Financing
CV Sciences, Inc. (CVSI) delivered earnings and revenue surprises of 100.00% and -7.98%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
CV Sciences, Inc. Reports Third Quarter 2021 Financial Results
SAN DIEGO, Nov. 15, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products...
